AI-generated from publicly available materials.The Sarah Cannon Research Institute (SCRI) has partnered with Merck & Co. to enhance the efficiency of community-based oncology trials, aiming to improve patient access and streamline drug development processes.
This collaboration will utilize SCRI’s Accelero delivery model, which focuses on overcoming challenges in oncology trials by optimizing health record data transfer, expediting site start-up, and increasing enrollment. The model is designed to connect trial sponsors with SCRI's extensive network of oncology sites, enhancing overall trial efficiency.
SCRI reports that the Accelero model has shown significant improvements, achieving site activations up to 50% faster than traditional methods and increasing enrollment rates by 19% above the national average. Additionally, it has minimized data changes during the research process, which can often complicate trial management.
This partnership reflects a broader trend in the industry, as SCRI has previously collaborated with other major pharmaceutical companies to facilitate similar advancements in clinical research. The ongoing commitment from both SCRI and Merck to innovate in cancer treatment underscores the importance of making clinical trials more accessible to patients, ultimately aiming to accelerate the delivery of new therapies.